Baolong Nguyen, MD
Gastroenterology · Midwest City, OKNPI 1710962071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 432 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 29.0% of the total.
Across 432 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Gilead$977
- Sanofi$348
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$266
- plus $2K from 25 others
Across 16 payments — averaging $4084.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$65K
What the payments were for
- Travel & lodging$2303%
- Food & beverage$8,39796%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $2,526 |
| Johnson & Johnson | 81 | $1,488 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $1,088 |
| Gilead | 53 | $977 |
| Sanofi | 14 | $348 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $266 |
| Bristol Myers Squibb | 16 | $259 |
| Regeneron Healthcare Solutions, Inc. | 7 | $248 |
| Boston Scientific | 1 | $230 |
| Intercept Pharmaceuticals, Inc. | 11 | $192 |
| Pfizer | 10 | $149 |
| Nestle Healthcare Nutrition Inc. | 7 | $140 |
| Cook Medical LLC | 1 | $138 |
| Lilly USA, LLC | 5 | $120 |
| Madrigal Pharmaceuticals | 3 | $97 |
| Medtronic | 1 | $64 |
| Ironwood Pharmaceuticals, Inc | 4 | $54 |
| Merck | 3 | $45 |
| QOL Medical, LLC | 3 | $39 |
| Organogenesis Inc. | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Ardelyx, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| Redhill Biopharma Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Shionogi Inc | 1 | $12 |
| Micro-tech Endoscopy USA, Inc. | 1 | $9 |
| Romark Laboratories, LC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$339
- DUPIXENT$246
- GENERAL - BILIARY DEVICES$230
- Tremfya$148
- EchoTip$138
How this compares
$8,718 in reported general payments places this provider in the 70th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 19 | $47,033 |
| VemlidyTenofovir Alafenamide | 23 | $32,737 |
| LinzessLinaclotide | 48 | $29,628 |
| MovantikNaloxegol Oxalate | 23 | $10,288 |
| MotegrityPrucalopride Succinate | 11 | $5,503 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,499 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 80 | $1,402 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 83 | $1,358 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,171 |
| Omeprazole | 71 | $1,162 |
| Pantoprazole Sodium | 91 | $1,128 |
| Metoclopramide Hcl | 18 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,526 | $76,66167 claims |
| GileadVemlidy | $977 | $32,73723 claims |
| Redhill Biopharma Inc.Movantik | $20 | $10,28823 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,088 | $5,50311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Midwest City
- Sikandar MesiyaMidwest City$11K
- George SalemOklahoma City$1.2M
- Tauseef AliOklahoma City$536K
- Jeffrey HuntTulsa$155K
- Pooja SinghalOklahoma City$140K
- Hussein BitarOklahoma City$120K
- Trushar PatelOklahoma City$49K
- Neal KaushalEdmond$36K
- Matthew McBrideOklahoma City$33K
- Sanjay SikkaOklahoma City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.